Medical Device Network on MSN
ADA26: Dexcom’s G7 CGM helps TD2 diabetics not on insulin manage glucose levels
Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...
Researchers shared findings today at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. San ...
By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...
Zacks Investment Research on MSN
Dexcom reports positive CONNECT data for non-insulin diabetes
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...
This combined sensor-transmitter continuous glucose monitor (CGM) technology offers glucose values every 5 minutes. Sensors last for up to 10-15 days and provide alerts for high and low blood sugars ...
A Dexcom continuous glucose monitor (CGM) helped adults with type 2 diabetes not using insulin improve blood sugar control in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results